Payment overview · 2025
General Payments
$640.60
58 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Lee Vonderfecht, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRAND ISLAND, NE · NPI 1750949707
Verified facts
What the public records show
CMS Open Payments records show Thomas Lee Vonderfecht, MD received $640.60 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 46.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ubrelvy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $297.45 | 46.4% | 38 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $97.12 | 15.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.72 | 7.1% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $33.89 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.79 | 4.8% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $24.39 | 3.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.46 | 3.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.05 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.54 | 3.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.89 | 2.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.80 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.50 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $640.60 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $169.80 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $127.65 | 15 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $97.12 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.73 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.72 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.54 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 40 |
| Gabapentin | Gabapentin | 162 | 31 |
| Meloxicam | Meloxicam | 159 | 58 |
| Omeprazole | Omeprazole | 148 | 38 |
| Metformin Hcl | Metformin Hcl | 145 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 43 |
| Losartan Potassium | Losartan Potassium | 141 | 40 |
| Lisinopril | Lisinopril | 123 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 27 |
| Allopurinol | Allopurinol | 105 | 23 |
| Potassium Chloride | Potassium Chloride | 90 | 20 |
| Carvedilol | Carvedilol | 88 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 26 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Trazodone Hcl | Trazodone Hcl | 78 | 20 |
| Simvastatin | Simvastatin | 77 | 21 |
| Enalapril Maleate | Enalapril Maleate | 75 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 17 |
| Ozempic | Semaglutide | 74 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 73 | 73 |
| Furosemide | Furosemide | 67 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 50 |
| Eliquis | Apixaban | 59 | 12 |
| Tramadol Hcl | Tramadol Hcl | 57 | 20 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Alprazolam | Alprazolam | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 23 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | suppressed |
| Famotidine | Famotidine | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Prednisone | Prednisone | 43 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 34 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 16 |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Ubrelvy | Ubrogepant | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Cephalexin | Cephalexin | 27 | 25 |
| Mupirocin | Mupirocin | 27 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Torsemide | Torsemide | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Glipizide | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $640.60 · 58 records | ABBVIE INC. | CAPVAXIVE, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, Ozempic, QULIPTA, REXULTI, REZDIFFRA, ROTATEQ, Rybelsus, SPRAVATO, TRINTELLIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, XIFAXAN, Xhance | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error